AstraZeneca PLC (AZN)vsSinovac Biotech Ltd (SVA)
AZN
AstraZeneca PLC
$185.95
-0.83%
HEALTHCARE · Cap: $282.69B
SVA
Sinovac Biotech Ltd
$6.47
0.00%
HEALTHCARE · Cap: $642.44M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 11736% more annual revenue ($60.44B vs $510.62M). SVA leads profitability with a 21.6% profit margin vs 17.2%. AZN appears more attractively valued with a PEG of 1.39. SVA earns a higher WallStSmart Score of 80/100 (A-).
AZN
Buy64
out of 100
Grade: C+
SVA
Exceptional Buy80
out of 100
Grade: A-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Intrinsic value data unavailable for SVA.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 42.3%
Revenue surging 303.7% year-over-year
Earnings expanding 354.8% YoY
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
Expensive relative to growth rate
ROE of -6.4% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : SVA
The strongest argument for SVA centers on P/E Ratio, Price/Book, Operating Margin. Profitability is solid with margins at 21.6% and operating margin at 42.3%. Revenue growth of 303.7% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : SVA
The primary concerns for SVA are Market Cap, Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
AZN profiles as a mature stock while SVA is a growth play — different risk/reward profiles.
AZN carries more volatility with a beta of 0.21 — expect wider price swings.
SVA is growing revenue faster at 303.7% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
SVA scores higher overall (80/100 vs 64/100), backed by strong 21.6% margins and 303.7% revenue growth. Both earn "Exceptional Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Sinovac Biotech Ltd
HEALTHCARE · BIOTECHNOLOGY · China
Sinovac Biotech Ltd., a biopharmaceutical company, focuses on the research, development, manufacture and marketing of vaccines against human infectious diseases in the People's Republic of China. The company is headquartered in Beijing, the People's Republic of China.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?